Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid) and a study from Sweden regarding increased risk of blot clots for myeloma patients. Dr. Berenson also previews the topics that he believes will be important for patients at the upcoming ASCO conference.
Understanding Myeloma News About Secondary Cancers and Clotting
About admin
View all posts by admin →Subscribe
Related Posts:
- Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study
- IMBCR & Emory University’s Big Discovery!!!
- James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
James R. Berenson, MD
- President & CEO, Institute for Myeloma & Bone Cancer Research (IMBCR)
- President & Medical Director. Berenson Cancer Center (Berensoncancercenter)
- Founder & President, ONCOtherapeutics
- Founder & Principal, ONCOtracker
Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:
- Monoclonal gammopathy of undetermined significance (MGUS)
- Asymptomatic (smoldering/indolent) myeloma
- solitary plasmacytoma of the bone
- Extramedullary plasmacytoma
- Light chain myeloma
- Non-secretory myeloma
- Osteosclerotic myeloma (POEMS syndrome)
- Waldenstrom macroglobulinemia
- Light chain amyloidosis
- Plasma cell leukemia
-
Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study February 8, 2022
-
IMBCR & Emory University’s Big Discovery!!! February 7, 2022
-
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center February 6, 2022
- What Is Multiple Myeloma? January 10, 2019
-
Video Updates June 26, 2018
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients February 16, 2011
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo March 19, 2011
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting November 23, 2011
- Understanding Myeloma News About Secondary Cancers and Clotting May 28, 2012
-
Dedication of “Determination” June 1, 2012
accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma
ASCO
B-cell maturation antigen
BCMA
Biomarker
Bortezomib
bortezomib; carfilzomib; multiple myeloma; proteasome inhibitor; relapsed; refractory
Carfilzomib
Dedication
HevyLite; immunoglobulins; multiple myeloma; outcomes
IMBCR
Kyprolis
lenalidomide
monoclonal antibodies
more is not better
Multiple Myeloma
myeloma
Overall survival
Pomalyst
proteasome inhibitors
Revlimid
Secondary Cancers
TRAF6
transplant
update
May 28, 2012
Press Releases